# Activity of Valomaciclovir in Infectious Mononucleosis Due to Primary Epstein-Barr Virus Infection

> **NCT00575185** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Minnesota** · enrollment: 23 (actual)

## Conditions studied

- Infectious Mononucleosis

## Interventions

- **DRUG:** Valomaciclovir
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00575185
- **Lead sponsor:** University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2009-07
- **Final completion:** 2010-02
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2017-03-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00575185

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00575185, "Activity of Valomaciclovir in Infectious Mononucleosis Due to Primary Epstein-Barr Virus Infection". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00575185. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*